SELLAS Life Sciences Group, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-26.9M | $-30.9M | $-37.3M | $-41.3M | $-20.7M | $-16.8M | $-19.3M | $-27.7M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | $0 |
| Stock-Based Compensation | $2.0M | $1.6M | $2.1M | $1.7M | $1.0M | $578.0K | $573.0K | $395.0K |
| Net Cash from Operating Activities | $-28.4M | $-35.4M | $-31.4M | $-23.8M | $-26.0M | $-10.4M | $-17.6M | $-30.4M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $0 | $-5.5M | $-4.5M | $0 | — | — | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | $0 | $487.0K |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $86.3M | $46.8M | $22.3M | $24.1M | $12.1M | $38.4M | $19.6M | $23.1M |
| Net Change in Cash | $57.9M | $11.4M | $-14.6M | $-4.2M | $-13.9M | $28.0M | $1.9M | $-7.3M |
| Free Cash Flow | — | — | — | — | — | — | — | — |